These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 12893358)
21. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209 [TBL] [Abstract][Full Text] [Related]
22. [First line indications for hormonal therapy in prostate cancer]. Boccon-Gibod L; Richaud P; Coloby P; Coulange C; Culine S; Davin JL; Soulié M; Zerbib M Prog Urol; 2010 Feb; 20(2):109-15. PubMed ID: 20142051 [TBL] [Abstract][Full Text] [Related]
23. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Marks LS Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507 [TBL] [Abstract][Full Text] [Related]
28. Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Li Q; Coulson H; Klaassen Z; Sharma S; Ramalingam P; Moses KA; Terris MK Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):387-90. PubMed ID: 24100643 [TBL] [Abstract][Full Text] [Related]
30. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866 [TBL] [Abstract][Full Text] [Related]
31. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Moreau JP; Delavault P; Blumberg J Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109 [TBL] [Abstract][Full Text] [Related]
32. [Post-radiation dedifferentiation of meningioma into chondroblastic osteosarcoma]. Svajdler M; Bohus P; Rychlý B; Sulla I; Moram M Cesk Patol; 2009 Jan; 45(1):20-3. PubMed ID: 19402318 [TBL] [Abstract][Full Text] [Related]
33. Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma. Ware ML; Larson DA; Sneed PK; Wara WW; McDermott MW Neurosurgery; 2004 Jan; 54(1):55-63; discussion 63-4. PubMed ID: 14683541 [TBL] [Abstract][Full Text] [Related]
34. Radical treatment strategies improve the long-term outcome of recurrent atypical meningiomas. Li F; Lai ZP; Lin JK; Zhu G; Feng H Chin Med J (Engl); 2011 Aug; 124(15):2387-91. PubMed ID: 22029080 [TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy. Ryu JH; Kim SJ; Kim YB; Jung TY; Ko WJ; Kim SI; Kim DY; Oh TH; Moon KT; Cho HJ; Cho JM; Yoo TK Aging Male; 2018 Mar; 21(1):17-23. PubMed ID: 28828908 [TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344 [TBL] [Abstract][Full Text] [Related]
39. Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate. González SV; Pijuan XM BJU Int; 2011 Apr; 107(8):1200-8. PubMed ID: 21078049 [TBL] [Abstract][Full Text] [Related]
40. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]